Hot Diversified Bank Companies To Watch In Right Now

Anybody who was lucky enough to get into a Recon Technology, Ltd. (NASDAQ:RCON) position before October 7th, then congratulations - you're up big-time. Now get out. Instead, a better use of that capital is Mitek Systems, Inc. (NASDAQ:MITK). While RCON is overbought and ripe for a pullback, MITK is itching to stage a breakout.

The outlooks for both stocks won't be particularly well-received ... especially for Recon Technology, which has become one of the market's most-loved darlings since late last month, with shares rallying as much as 140% since the end of September. The weight of those gains is starting to take a toll now. As for Mitek Systems, while suggesting it is a buy won't create any ire, traders are probably aware it's been weak since June, and stuck in a range since July. The explanation for both calls is, nothing lasts forever.

Hot Diversified Bank Companies To Watch In Right Now: Central Garden & Pet Company(CENT)

Central Garden & Pet Company produces and sells products for the pet, and lawn and garden supplies industries primarily in the United States. The company?s pet supplies products comprise products for dogs and cats, including edible bones, premium healthy edible and non-edible chews, dog and cat food and treats, leashes, collars, toys, pet carriers, grooming supplies, and other accessories; products for birds, small animals, and specialty pets, such as food, cages and habitats, toys, chews, and related accessories; animal and household health, and insect control products; products for fish, reptiles, and other aquarium-based pets comprising aquariums, furniture and lighting fixtures, pumps, filters, water conditioners, food and supplements, and information and knowledge resources; and products for horses and livestock. It sells its pet supplies products under the Adams, Altosid, Aqueon, Avoderm, BioSpot, Breeder?s Choice, Coralife, Farnam, Four Paws, Interpet, Kaytee, Ken t Marine, Nylabone, Oceanic Systems, Pet Select, Pre-Strike, Pinnacle, Super Pet, TFH, Zilla, and Zodiac brand names. The company?s lawn and garden supplies products include grass seed; wild bird feed, bird feeders, bird houses, and other birding accessories; weed, grass, ant and other herbicide, insecticide, and pesticide products; and decorative outdoor lifestyle and lighting products, such as pottery, trellises and other wood products, and holiday lighting products. It offers its lawn and garden supplies products under the AMDRO, GKI/Bethlehem Lighting, Grant?s, Ironite, Lilly Miller, Matthews Four Seasons, New England Pottery, Norcal Pottery, Pennington, Over?n Out, Sevin, Smart Seed, and The Rebels brand names. It sells its products principally to independent pet and garden distributors, national and regional retail chains, grocery stores, mass merchants, home improvement centers, nurseries, and garden supply retailers. The company was founded in 1955 and is based in Walnut Creek, California.

Advisors' Opinion:

• [By Sean Williams]

  Green paw
  The month of May has been one to forget for shareholders of Central Garden & Pet (NASDAQ: CENT  ) (NASDAQ: CENTA  ) . The maker of pet products as well as seeds and herbicides for lawn care tumbled after it missed Wall Street's earnings estimates for a second straight quarter. The biggest downside pressure came from its lawn care segment, which saw expenses rise as fertilizer margins fell. However, now could be the time to consider jumping on board this interesting pet/lawn care hybrid company, as it has the potential to unlock shareholder value in a number of ways.

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Central Garden & Pet (Nasdaq: CENT  ) , whose recent revenue and earnings are plotted below.

Hot Diversified Bank Companies To Watch In Right Now: Cutera Inc. (CUTR)

Cutera, Inc., a medical device company, engages in the research, design, development, manufacture, marketing, sale, and service of laser and other energy based aesthetics systems for practitioners worldwide. The company offers a range of non-invasive laser and intense pulsed light products for use in the treatment of cosmetic vascular conditions, hair removal, vascular lesions, skin rejuvenation, onychomycosis or toenail fungus, pigmented lesions, laser skin toning, tattoo removal, cutaneous lesions, fine wrinkles, diffuse redness, rosacea, skin texture, and pore size, as well as for non-invasive body contouring applications. It primarily serves plastic surgeons, dermatologists, gynecologists, primary care physicians, family practitioners, physicians offering aesthetic treatments in non-medical offices, podiatrists, and other qualified practitioners. The company sells and markets its products through its direct sales force and distributors, as well as sells hand piece refi lls through the Internet. Cutera, Inc. was founded in 1998 and is headquartered in Brisbane, California.

Advisors' Opinion:

• [By John Udovich]

  Large cap serial acquirer�Valeant Pharmaceuticals International Inc (NYSE: VRX) is teaming up with activist investor�Bill Ackman to pursue large cap Botox maker Allergan, Inc (NYSE: AGN), but stocks like Cutera, Inc (NASDAQ: CUTR), Cynosure, Inc (NASDAQ: CYNO), PhotoMedex Inc (NASDAQ: PHMD) and Syneron Medical Ltd (NASDAQ: ELOS)�actually offer investors more exposure to the growing anti aging and aesthetics market (Note: See my recent article: These Small Caps Seek to Treat Your Crow�� Feet and Double Chin (RVNC & KYTH)). To begin with, Valeant Pharmaceuticals International has a wide focus on neurology, dermatology and infectious diseases�but acquiring the maker of Botox won�� be its first foray into the aesthetic market�because earlier this year, the company completed its acquisition of Solta Medical Inc (NASDAQ: SLTM) -�a designer, developer, manufacturer and marketer of�energy-based medical device systems for aesthetic applications.�And while�Allergan, Inc may be most well known for Botox, its actually a pretty big�company focused on a diverse range of areas, including ophthalmic pharmaceuticals, dermatology, neuroscience, urology and cosmetics���meaning the following stocks offer investors better exposure to the aesthetics market:

Best Energy Stocks To Watch Right Now: ZELTIQ Aesthetics Inc (ZLTQ)

ZELTIQ Aesthetics, Inc. (ZELTIQ), incorporated on March 22, 2005, is a medical technology company. The Company is focused on developing and commercializing products utilizing its controlled-cooling technology platform. Its commercial product is the CoolSculpting System that reduces stubborn fat bulges. The Company generates revenues from capital sales of its CoolSculpting System and from procedure fees its physician customers pay for each CoolSculpting procedure they perform. As of March 31, 2011, it had an installed base of 346 and 475 CoolSculpting Systems worldwide and over 88,000 CoolSculpting procedures had been sold to its physician customers. The Company markets CoolSculpting to the dermatologists, plastic surgeons, and aesthetic specialists. As of March 31, 2011, ZELTIQ�� North American direct sales force consisted of 23 professionals, and over 88,000 CoolSculpting procedures were sold to ZELTIQ�� physician customers.

CoolSculpting System

ZELTIQ generates revenues from capital sales of its CoolSculpting System and from procedure fees its physician customers pay for each CoolSculpting procedure they perform. Capital sales of ZELTIQ�� CoolSculpting System include the CoolSculpting control unit and its CoolSculpting vacuum applicators. ZELTIQ generates procedure fees through sales of CoolSculpting procedure packs, which include its consumable gelpads and liners and a disposable computer cartridge that it markets as the CoolCard. The CoolCard contains enabling software that permits its physician customer to perform a fixed number of CoolSculpting procedures.

The CoolSculpting control unit is the base of the CoolSculpting System. ZELTIQ�� CoolSculpting control unit also contains software that tracks and collects data about each procedure performed and any error messages that may be generated during the procedure. CoolSculpting System includes three CoolSculpting vacuum applicators. ZELTIQ�� CoolSculpting procedure packs facilitate the pay-per-procedu! re feature of its CoolSculpting System. Its CoolSculpting procedure packs include CoolCard and its consumable gelpads and liners.

Advisors' Opinion:

• [By John Udovich]

  On Tuesday, small cap biotech stock Kythera Biopharmaceuticals Inc (NASDAQ: KYTH) surged around 25% after announcing that its ATX-101 REFINE-1 and REFINE-2 Phase III trials met all primary and secondary endpoints for the reduction of so-called double chins; but if investors missed out on that rally, small caps Zeltiq Aesthetics Inc (NASDAQ: ZLTQ), Solta Medical Inc (NASDAQ: SLTM) and Cynosure, Inc (NASDAQ: CYNO) each have a piece of the aesthetic market as well. In the case of Kythera Biopharmaceuticals, its ATX-101 can be injected to deal with double chins���meaning its less invasive than liposuction as the drug dissolves fat cells but leaves other tissue alone. JP Morgan has noted:

Hot Diversified Bank Companies To Watch In Right Now: Sino-Global Shipping America Ltd.(SINO)

Sino-Global Shipping America, Ltd., through its subsidiaries, provides shipping agency services for foreign ships coming to and departing from Chinese ports. Its services include preparing documents, husbanding vessels, working through customs issues, coordinating matters with port authorities, overseeing and settling cargo claims, tracking shipments, recommending trucking, warehousing, and complementary services. The company offers these services for bulk and break-bulk general cargo, and vehicle transport, as well as raw materials, such as crude oil, oil products, iron, manganese, and other metal ores in 76 ports in the People?s Republic of China. Sino-Global Shipping America, Ltd. was founded in 2001 and is based in Flushing, Virginia.

Advisors' Opinion:

• [By James E. Brumley]

  The recent strength from Sino-Global Shipping America, Ltd. (NASDAQ:SINO) and the now-renewed strength from Safe Bulkers, Inc. (NYSE:SB) would suggest those two stocks are among the very best ways to play the rebound currently unfurling in the shipping sector. And to be fair, both are fine companies in their own right. The top play in the dry goods maritime shipping arena, however, may well be Diana Shipping Inc. (NYSE:DSX). No, DSX isn't one of the fun and exciting small caps in the maritime shipping space. But, there's a lot to be said for size and stability, which SB and SINO can't offer.

Hot Diversified Bank Companies To Watch In Right Now: Lockheed Martin Corporation(LMT)

Lockheed Martin Corporation engages in the research, design, development, manufacture, integration, operation, and sustainment of advanced technology systems and products in the areas of defense, space, intelligence, homeland security, and government information technology in the United States and internationally. It also provides management, engineering, technical, scientific, logistic, and information services. The company operates in four segments: Aeronautics, Electronic Systems, Information Systems & Global Services (IS&GS), and Space Systems. The Aeronautics segment offers military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. Its products and programs comprise the F-35 multi-role, stealth fighter; the F-22 air dominance and multi-mission stealth fighter; the F-16 multi-role fighter; the C-130J tactical transport aircraft; and the C-5M strategic airlifter modernization program; and support for the P-3 maritime patrol aircraft, and the U-2 high-altitude reconnaissance aircraft. The Electronic Systems segment provides air and missile defense; tactical missiles; weapon fire control systems; surface ship and submarine combat systems; anti-submarine and undersea warfare systems; land, sea-based, and airborne radars; surveillance and reconnaissance systems; simulation and training systems; and integrated logistics and sustainment services. The IS&GS segment offers information technology solutions and advanced technology primarily in the areas of software and systems integration for space, air, and ground systems to various defense and civil government agencies. The Space Systems segment provides government and commercial satellites; strategic and defensive missile systems, including missile defense technologies and systems, and fleet ballistic missiles; and space transportation systems. Lockheed Martin Corporation was founded in 1909 and is based in Bethesda, Maryland.

Advisors' Opinion:

• [By Victor Selva]

  Competitors such as AEP Industries Inc. (AEPI) and Lockheed Martin Corporation (LMT) will be better options in term of ROE.

  Final Comment

Hot Diversified Bank Companies To Watch In Right Now: Open Text Corporation (OTEX)

Open Text Corporation develops, markets, sells, licenses, and supports enterprise content management (ECM) solutions primarily in North America and Europe. The company?s ECM software and solutions enable customers to manage various types of enterprise content, including business documents, Web content, records, digital assets, email, forms and reports, forums, blogs, wikis, and real time instant messaging and collaboration. Its ECM solutions comprise various components, including document management, which provides repository for business documents, such as Microsoft office, CAD, and PDF; collaboration that offers tools designed to better facilitate people working with each other with content and processes; Web content management, which provides tools for authoring, maintaining, and administering sophisticated Web sites; and records management that enables control of the lifecycle of content objects by associating robust retention and disposition rules with each content as set. The company?s ECM solutions also provide email management services designed to enable the archiving, control, and monitoring of email; capture and delivery tools that provide the means of converting documents from analog sources; digital asset management; business process management services; content reporting tools for analyzing content and generating reports; and Open Text Everywhere that allows the Open Text ECM suite to be available via mobile devices. In addition, it offers industry specific solutions for government, technology/manufacturing, energy, financial services, pharmaceutical and life sciences, legal, and media sectors. Additionally, the company provides learning, consulting, hosting, and customer support and training services. It has strategic alliances with Microsoft Corporation, Oracle Corporation, and SAP AG. The company was founded in 1991 and is headquartered in Waterloo, Canada.

Advisors' Opinion:

• [By Seth Jayson]

  OpenText (Nasdaq: OTEX  ) is expected to report Q3 earnings on April 24. Here's what Wall Street wants to see:

  The 10-second takeaway
  Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict OpenText's revenues will grow 18.1% and EPS will grow 28.7%.

Hot Diversified Bank Companies To Watch In Right Now: CytRx Corporation(CYTR)

CytRx Corporation, a biopharmaceutical research and development company, engages in the development of human therapeutics, specializing in oncology. Its drug development pipeline includes INNO-206, which is in Phase II clinical trials for the treatment of soft tissue sarcomas and is in Phase Ib/2 clinical trials for the treatment of solid tumors; and tamibarotene that is in Phase II clinical trials for the treatment of non-small-cell lung cancer and acute promyelocytic leukemia. The company also develops Bafetinib, which is in Phase II clinical trials for the treatment of B-cell chronic lymphocytic leukemia and advanced prostate cancer, as well as in pharmacokinetic clinical trial for brain cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

Advisors' Opinion:

• [By Lauren Pollock]

  Biopharmaceutical development company CytRx Corp.(CYTR) and early-stage diagnostics company Cancer Genetics Inc.(CGIX) separately disclosed plans to sell stock. CytRx, whose offering of 10 million shares priced at an 18% discount, is aiming to raise money to fund its clinical trials, while Cancer Genetics wants to hire more sales and marketing personnel, as well as fund research and development. CytRx dropped, while Cancer Genetics fell.

• [By Bryan Murphy]

  Just for the record, not all my stock picks are great ones. Most are pretty good, some are just so-so, and every now and then they may even be spectacularly bad. Two of the recent ones, however, are looking like they're falling right into place... InterCloud Systems Inc. (NASDAQ:ICLD) and CytRx Corporation (NASDAQ:CYTR). If you didn't catch the first write-ups or weren't sure about CYTR or ICLD at the time, both budding moves are looking even more likely today.

• [By James Johnson]

  CytRx Corporation's (NASDAQ: CYTR  ) oncology drug, aldoxorubicin, an improved version of the chemotherapeutic agent doxorubicin, recently received FDA approval to extend the dosing in a Phase 3 clinical trial. This trial is evaluating aldoxorubicin as a second-line treatment for soft-tissue sarcomas (STS). In April 2013, the FDA granted Special Protocol Assessment (SPA) to aldoxorubicin as a second-line treatment for STS with a maximum dosing of six cycles. The drug is given by a 30 minute IV infusion once every three weeks which is one cycle. The extension of the treatment cycle was based on aldoxorubicin's superior cardiac safety and efficacy profile compared to doxorubicin in prior studies. Aldoxorubicin was found to be safer than doxorubicin, a toxic drug associated with side effects such as cardiovascular events and heart damage in cancer patients. The extended dosing could allow CytRx to demonstrate even higher progression-free survival (PFS) efficacy results compared to the Phase 2b trial for advanced STS with this drug. The company plans to initiate the Phase 3 trial during the first quarter of 2014.